Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor

Bioorganic & Medicinal Chemistry Letters
2020.0

Abstract

A series of Torin2, a second-generation ATP-competitive inhibitor, analogues were biologically characterized to identify their potential for ATR and mTOR kinase inhibition. Compound SPK 98 was observed to inhibit ATR/mTOR kinase selectively over ATM kinase in HCT 116 cell line. In addition to that, SPK 98 on 30 min incubation with human, mice and rat liver microsomes showed improved properties with an increased half-life (a maximum T ½ of 157 min) and internal clearance in mouse as compared to Torin2. Further, SPK 98 was also noticed to indulge in inducing premature chromatin condensation as a result of ATR/mTOR kinase inhibition at 50 nM. In a nutshell, our work presents the identification and characterization of SPK 98, a small molecule inhibitor, which exhibits improved specific inhibition for ATR at a lower concentration than Torin2.

Knowledge Graph

Similar Paper

Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor
Bioorganic & Medicinal Chemistry Letters 2020.0
Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
Journal of Medicinal Chemistry 2011.0
Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer
Journal of Medicinal Chemistry 2018.0
Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
Journal of Medicinal Chemistry 2011.0
N-Aryl-benzimidazolones as novel small molecule HSP90 inhibitors
Bioorganic & Medicinal Chemistry Letters 2010.0
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors
ACS Medicinal Chemistry Letters 2018.0
Molecular Characterization of Macbecin as an Hsp90 Inhibitor
Journal of Medicinal Chemistry 2008.0
Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0
Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity
Journal of Medicinal Chemistry 2012.0
Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study
European Journal of Medicinal Chemistry 2022.0